

ASX ANNOUNCEMENT

27 July 2026

Investor Webinar: Q4 FY26 Results and International Markets

- Investor Webinar: Monday 3 August 2026, 10.00am–10.45am AEST, covering:
 - Q4 FY26 quarterly results (Appendix 4C), to be lodged on Wednesday 29 July 2026 before market open
 - FY26 International Markets presentation, to be released to the ASX on Monday 27 July 2026 ahead of the webinar
- [Registration link](#)

Microbiome health company *Biome Australia Limited* (ASX: BIO) ('*Biome*' or '*the company*') is pleased to invite investors to *the company's* Investor Webinar on Monday 3 August 2026 from 10.00am–10.45am AEST.

Hosted by *Biome Australia's* Founder and Managing Director, Blair Vega Norfolk, joined by Chief Financial Officer, Lauren Dwyer, the Investor Webinar will cover *the company's* Q4 FY26 quarterly results and Appendix 4C, to be lodged with the ASX on Wednesday 29 July 2026 before market open, and the FY26 International Markets presentation, to be released to the ASX on 27 July 2026.

The International Markets presentation covers *the company's* four active international markets; Canada, the United Kingdom, Ireland and New Zealand. The presentation will include channel and distribution partners, competitive positioning, the Ireland-based EU-gateway hub, onshore manufacturing, and the *Biome* B2B2C direct wholesale and e-script portal planned for H1 FY27.

Investors are encouraged to register in advance. The webinar will include a live Q&A; questions may be submitted ahead of the session via email to corporate@biomeaustralia.com.

Register: https://us02web.zoom.us/webinar/register/WN_dy8dV-AhQaSnmfMRm8-rLw

–ENDS–

Approved for release by the Biome Australia board of directors.

Investor Hub

Biome has an interactive investor hub. To view a previous presentation or sign up for future company updates, please visit the investor hub at <https://investorhub.biomeaustralia.com/>.

About Biome Australia Limited

Biome Australia develops, licences, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. *Biome* aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, *Biome* distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, *Biome* produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: *Activated Probiotics*®.

Supported by clinical research, including randomised double-blind placebo-controlled trials, *Activated Probiotics* and *Activated Therapeutics* help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, *Biome* is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations

Lauren Dwyer
corporate@biomeaustralia.com
(03) 9017 5800

Forward Looking Statements

This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of *Biome* (Forward Looking Statements). Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of *Biome*'s business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Patent applications are subject to examination processes and grant is not guaranteed. Clinical trial results cannot be predicted and may not support commercial development. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

